Physician profile
Jaime Barker
NPI 1174668735
$3,933.17
in general payments reported to CMS, 2019-2025
15 companies · $592 in 2025
The $592 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $115 · 2022: $572 · 2023: $853 · 2024: $833 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $497.04 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $474.29 | 2023-2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $463.89 | 2019-2023 | Xywav |
| Janssen Pharmaceuticals, INC | $372.32 | 2022-2024 | Spravato |
| Neurocrine Biosciences, INC. | $364.76 | 2023-2025 | Ingrezza |
| Allergan, INC. | $339.65 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $325.19 | 2019-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $267.48 | 2019 | |
| Alkermes, INC. | $196.48 | 2022-2024 | Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $150.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.98 | 2024 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $123.42 | 2023 | Qelbree |
| Abbvie INC. | $109.49 | 2022 | |
| Tms Neurohealth Centers INC. | $101.86 | 2025 | Tms Neurohealth Centers INC. |
| Bayer Healthcare Pharmaceuticals INC. | $22.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.